[Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C.
Encephale. 2014 Feb;40(1):86-94. doi: 10.1016/j.encep.2012.03.002. Epub 2013 Aug 5.
Current status of contraceptive steroids and the intrauterine device.
Mishell DR Jr.
Clin Obstet Gynecol. 1974 Mar;17(1):35-51. doi: 10.1097/00003081-197403000-00007.
The fallacy of the postpill amenorrhea syndrome.
Archer DF, Thomas RL.
Clin Obstet Gynecol. 1981 Sep;24(3):943-50. doi: 10.1097/00003081-198109000-00019.
Clinical review 15: Management of ovulatory disorders with pulsatile gonadotropin-releasing hormone.
Martin K, Santoro N, Hall J, Filicori M, Wierman M, Crowley WF Jr.
J Clin Endocrinol Metab. 1990 Nov;71(5):1081A-1081G. doi: 10.1210/jcem-71-5-1081.
[Neuro-MR-findings in primary panhypopituitarism].
Fellner F, Triebe S, Hensen J, Baum U, Schmitt R, Flottemesch J, Bautz W.
Rontgenpraxis. 1998;51(7):243-7.
Formulation and noncontraceptive uses of the new, low-dose oral contraceptive.
Batzer FR.
J Reprod Med. 1984 Jul;29(7 Suppl):503-12.
Absence of desensitization by hexarelin to subsequent GH releasing hormone-mediated GH secretion in patients with anorexia nervosa.
Popovic V, Micic D, Djurovic M, Obradovic S, Casanueva FF, Dieguez C.
Clin Endocrinol (Oxf). 1997 May;46(5):539-43. doi: 10.1046/j.1365-2265.1997.1650982.x.
Gonadotropin releasing hormone test: diagnostic significance and limits in menstrual pathology.
Venturoli S, Nardi M, De Aloysio D, Magrini O, Flamigni C.
Acta Eur Fertil. 1976 Mar;7(1):1-38.
